Doctor, researcher and professor María José Torres is the first Spaniard to hold this position. She will be president for the next two years, having previously held the post of secretary general.
Dr. María José Torres Jaén is Professor in the Department of Medicine at the University of Malaga, Head of the Allergology Service at the Regional University Hospital of Malaga, Principal Investigator of the Allergic Diseases to Drugs and Allergens research group at the Biomedical Research Institute of Malaga and BIONAND Platform (IBIMA Plataforma BIONAND) and, as of this month, President of the European Academy of Allergy and Clinical Immunology (EAACI).
EAACI is Europe's leading source of expertise on all aspects of allergic diseases. It is an association of researchers and professionals in the field that aims to improve the health of people affected by allergic diseases through collaboration between researchers, networking among its more than 15,000 members from 124 countries and more than 50 national allergy societies.
The inauguration took place at the Closing Ceremony of the EAACI annual congress in Valencia. In her speech, in the context of the plenary session ‘Drug allergy: today and tomorrow’, Dr Torres emphasised the need for further international research - a task that EAACI facilitates by acting as a link between clinical and basic researchers - explaining that ‘drug allergy is a challenge for healthcare systems and can, in some cases, put patients’ lives at risk’. Indeed, in recent years there has been increasing interest in developing tools and models to identify patients at risk. In this sense, and according to Dr. Torres, ‘it is essential that we continue researching and working to achieve the goal of implementing efficient precision medicine’.
Her appointment to the presidency of this internationally prestigious institution is the result of a long and brilliant professional career in healthcare, research and teaching. María José is the author of more than 300 publications in high-impact international journals, 400 communications at conferences and has given more than 50 lectures. She is also a founding partner of Bioherent, a spin-off of the University of Malaga, has 9 patents, one of which has been exploited by industry, and has led 22 competitive research projects at regional, national and European level.
Raúl J. Andrade Bellido, es Investigador Responsable del grupo consolidado ‘Hepatogastroenterología, Farmacología y Terapéutica Clínica Traslacional’ de IBIMA Plataforma BIONAND, Catedrático y Director del Departamento de Medicina en la Facultad de Medicina de la Universidad de Málaga, Jefe de Servicio Aparato Digestivo del Hospital Universitario Virgen de la Victoria en Málaga. Además, es el Responsable del Grupo Español de Hepatopatias asociadas a medicamentos (Spanish DILI Registry), el Coordinador de la Red Ibero-Americana de Hepatopatías asociadas a medicamentos (SLATINDILI) y también del Registro europeo de Hepatopatías asociadas a Medicamentos (Pro-Euro DILI Registry). Chair de la COST Action CA17112 – Prospective European Drug-Induced Liver Injury Network (PRO-EURO DILI NET) y del EASL DHILI Consortium. Horizonte2020. Framework Programme (European Union).